key: cord-0814398-m1d7ybgm
authors: Grau-Expósito, Judith; Perea, David; Suppi, Marina; Massana, Núria; Vergara, Ander; Soler, Maria José; Trinite, Benjamin; Blanco, Julià; García-Pérez, Javier; Alcamí, José; Serrano-Mollar, Anna; Rosado, Joel; Falcó, Vicenç; Genescà, Meritxell; Buzon, Maria J.
title: Evaluation of SARS-CoV-2 Entry, Inflammation and New Therapeutics in Human Lung Tissue Cells
date: 2021-11-07
journal: bioRxiv
DOI: 10.1101/2021.04.21.440731
sha: f0dc4ec88f78ea6714d01b8cd175bcb2f0bf3d1c
doc_id: 814398
cord_uid: m1d7ybgm

The development of physiological models that reproduce SARS-CoV-2 infection in primary human cells will be instrumental to identify host-pathogen interactions and potential therapeutics. Here, using cell suspensions directly from primary human lung tissues (HLT), we have developed a rapid platform for the identification of viral targets and the expression of viral entry factors, as well as for the screening of viral entry inhibitors and anti-inflammatory compounds. The direct use of HLT cells, without long-term cell culture and in vitro differentiation approaches, preserves main immune and structural cell populations, including the most susceptible cell targets for SARS-CoV-2; alveolar type II (AT-II) cells, while maintaining the expression of proteins involved in viral infection, such as ACE2, TMPRSS2, CD147 and AXL. Further, antiviral testing of 39 drug candidates reveals a highly reproducible method, suitable for different SARS-CoV-2 variants, and provides the identification of new compounds missed by conventional systems, such as VeroE6. Using this method, we also show that interferons do not modulate ACE2 expression, and that stimulation of local inflammatory responses can be modulated by different compounds with antiviral activity. Overall, we present a relevant and rapid method for the study of SARS-CoV-2. Graphical Abstract Highlights Ex vivo physiological systems for the study of SARS-CoV-2-host interactions are scarce. Here, we establish a method using primary human lung tissue (HLT) cells for the rapid analysis of cell tropism and identification of therapeutics. HLT cells preserve main cell subpopulations, including alveolar type-2 cells, and expression of SARS-CoV-2 entry factors ACE2, CD147, TMPRSS2 and AXL. HLT cells are readily susceptible to SARS-CoV-2 infection without the need of cell isolation or further cell differentiation. Antiviral testing in HLT cells allows the rapid identification of new drug candidates against SARS-CoV-2 variants, missed by conventional systems. Local inflammation is supported in HLT cells and offers the identification of relevant anti-inflammatory compounds for SARS-CoV-2 infection.

Introduction effect on ACE2 expression was observed after the addition of these anti-inflammatory drugs 292 ( Figure 5B) . Consequently, tested anti-inflammatory compounds showed no major impact of the 293 viral entry assay; however, high concentrations of prednisone and dexamethasone showed a 294 partial reduction of viral entry in HLT cells, without any apparent impact on VeroE6 cells ( Figure  295 5C). Thus, selected anti-inflammatory drugs had limited impact on ACE2 expression within 296 enriched AT-II cells from the HLT model, as well as in SARS-CoV-2 viral entry. 297

Last, we were interested in modelling the anti-inflammatory properties of several drugs in 299 HLT cells. Based on their previous antiviral potency, we selected cepharanthine, ergoloid, 300 camostat, ivermectin, hydroxychloroquine and ciclesonide for further evaluation. Of note, some 301 of these drugs have been previously identified as immunomodulators with anti-inflammatory 302 effects (Table S1 ). However, their direct impact on inflammatory molecules directly secreted by 303 human lung cells have not been evaluated. HLT cells were stimulated with lipopolysaccharides 304 (LPS) and IFN-γ in the presence of these antivirals and, 20h after, the expression of IL-6 and 305 CXCL10, a potent pro-inflammatory cytokine and a chemokine respectively, were intracellularly 306 measured by flow cytometry. IL-6 and CXCL10 were selected as molecules significantly increased 307 in severe patients during acute infection, with a prediction value for hospitalization [55] . A 308 representative flow cytometry gating strategy is shown in Figure S4 . As shown in Figure 6A , two 309 major subpopulations of myeloid cells contributed to the upregulation of CXCL10 and IL-6 310 expression upon stimulation. Myeloid CD11b + CD14 + were the cells with a greater response, with 311 50% of these cells expressing IL-6 and 30% expressing CXCL10 after stimulation ( Figure 6B) . 312

Using this model of local inflammation, we tested the capacity of the selected compounds to 313 attenuate this response. We observed that camostat had the most potent effect, which 314 significantly reduced the expression of CXCL10 in CD11b + CD14and of IL-6 in CD11b + CD14 + 315 myeloid subsets ( Figure 6B) . Ergoloid, which has not been linked to modulation of inflammation 316 before, significantly reduced the expression of cytokines in CD11b + CD14 + myeloid cells, and 317 cepharanthine reduced IL-6 production within this same subset. In contrast, ciclesonide induced 318 CXCL10 secretion in CD11b + CD14myeloid cells ( Figure 6B) . Altogether, our results validate the 319 use of HLT cells as a relevant method for the identification of anti-inflammatory compounds 320 impacting specific pro-inflammatory cell populations located in the lung parenchyma.

The emergency created by the fast spread of SARS-CoV-2 infection worldwide required a 323 quick response from physicians treating these patients, who adapted to the rapid knowledge 324 being generated by both clinical practice and basic research. However, up to date, only one 325 antiviral drug against SARS-CoV-2 has been approved for clinical use. New antivirals are urgently 326 needed, and the choice of the cell and animal models used to test the efficacy of drugs will 327 impact its rapid translation into the clinics. Here, we propose the use of human lung tissue (HLT) 328 cells as a method that can be safely performed in a BSL2 facility, which allows i) the identification 329 of cell targets and expression of viral entry factors, ii) the impact of inflammation on host-330 pathogen interactions and iii) a rapid medium-high throughput drug screening of entry inhibitors 331 against SARS-CoV-2 variants and local anti-inflammatory candidates. 332

Using pseudotyped viral particles expressing the SARS-CoV-2 spike, we first corroborated that 333 a fraction of CD45 -CD31 -HLA-DR + and EpCam + is enriched in AT-II cells and are the primary cell 334 target in lung tissue in steady conditions. This agrees with several studies using different 335 approximations [12, 36, 56] and validates our primary model for viral tropism identification. 336

While cell lines have been traditionally used for the screening of potential antiviral compounds 337 due to their reproducibility, as well as being quick and user-friendly assays, they lack 338 physiological relevance. Similarly, entry receptors and viral factors have been identified using 339 immortalized cell lines [11, 57] , and cell targets for SARS-CoV-2 in tissues have been mainly 340 determined by analyzing the expression of viral entry factors in RNA-seq datasets [58] or using 341 replication-competent SARS-CoV-2 isolates in BSL3 facilities [59] . Importantly, these studies 342 have identified AT-II cells as main viral targets for SARS-CoV-2 infection in the lungs, and the 343 molecules ACE2, CD147, TMPRSS2 and AXL as important factors for viral entry [11, 34, 37, 60] . 344 However, the development of more refined and translational ex vivo models of SARS-CoV-2 345 entry will not only have implications for understanding viral pathogenesis, but also will be useful 346

for the characterization of cell targets under specific conditions or for the identification of 347 potential antivirals blocking viral entry in primary cells. The direct use of HLT cells allows the 348 maintenance of cell type diversity and it may represent a significant advantage over previous 349 models [18, 20, 61] . 350

Moreover, we showed that the HLT cells can be successfully used for drug screening 351 purposes, not only against the D614G virus but also against the delta variant. We tested 39 drugs 352 and compared the results with antiviral testing in VeroE6 cells. Not surprisingly, we showed 353 discordant results between both methods. Indeed, we found that 33.3% of the tested compounds had discordant results between HLT and VeroE6 cells; 26.66% of drugs showed some 355 antiviral effect in HLT but no activity was detected in VeroE6, and 6.67% showed only antiviral 356 effects in VeroE6 cells. Among other reasons, the differential expression of several key proteins 357 needed for viral entry, might explain current discrepancies between cell types. Importantly, 358 using HLT cells, we identified several compounds with antiviral activity; cepharanthine showed 359 an EC 50 of 6.08µM and concordantly, it was recently identified in a high throughput screening as 360 one of the most potent drugs against SARS-CoV-2 [62], likewise several other studies have 361 pointed towards this drug as a potent entry and post-entry SARS-CoV-2 inhibitor [63] . Instead, 362 for hydroxychloroquine, an early report suggested no antiviral activity in human lung cells due 363 to different expression of the required proteases for viral entry [64] . Furthermore, clinical trials 364 failed to show effectiveness of this drug as a treatment for . A strong 365 dependency of SARS-CoV-2 on TMPRSS2 for viral entry, rather than on cathepsin L, was 366 identified as a possible mechanistic explanation for its failure in vivo [68] . In our study, however, 367 we observed that this drug was equally effective at inhibiting viral entry in VeroE6 and HLT cells, 368 and also was effective when using replication competent viral isolates in HLT cells. Concordantly, 369 in differentiated air-liquid interface cultures of proximal airway epithelium and 3D organoid 370 cultures of alveolar epithelium, hydroxychloroquine significantly reduced viral replication [69] . 371

The multiple mechanisms of action postulated for hydroxychloroquine action, including 372 interference in the endocytic pathway, blockade of sialic acid receptors and restriction of pH 373 mediated S protein cleavage at the ACE2 binding site [70] , could help to explain its antiviral effect 374 in primary lung cells. Similarly, we identified ivermectin as an effective antiviral in HLT cells. Of 375 note, ivermectin received limited attention as a potential drug to be repurposed against COVID-376 19 based on its limited ability to reach lung tissue in vivo [71] . Further, a clinical trial failed to 377 show a reduction in the proportion of PCR-positive patients seven days after ivermectin 378 treatment [72] . 379 Importantly, HLT cells also provide a platform for testing anti-inflammatory drugs and the 380 modulation of viral entry factors with drug candidates and immunomodulatory stimuli. We 381 showed that IL-1β was able to reduce ACE2 expression in the fraction of enriched AT-II cells, in 382 contrast to other cytokines induced during SARS-CoV-2 infection like IFN-α2, IFN-β1, IL-10 and 383 GM-CSF, which did not impact ACE2 protein production. In primary epithelial cells derived from 384 healthy nasal mucosa, Ziegler et al. [12] showed a significant induction of ACE2 transcripts after 385 IFN-α2 and IFN-γ stimulation, as well as and in a human bronchial cell line treated with either 386 type I or type II IFN. Moreover, the authors showed that influenza A virus infection 387 increased ACE2 expression in lung resections [12] , strongly suggesting that ACE2 was an ISG. However, following studies showed that ACE2 transcription and protein production was not 389 responsive to IFN. Instead, they described a new RNA isoform, MIRb-ACE2, that was highly 390 responsive to IFN stimulation, but importantly, encoded a truncated and unstable protein 391 product [73, 74] . These results highlight the need to validate scRNA-seq data with orthogonal 392 approaches, such as the confirmation of protein expression levels in relevant systems. In HLT 393 cells, we quantified ACE2 protein expression and importantly, focused our analysis on putative 394 AT-II cells, the main SARS-CoV-2 targets in lung parenchyma. Also, in agreement with our results, 395 a primary human bronchial epithelial cell model, type I (β), II (γ), or III (λ1) IFNs did not induced 396 ACE2 expression [75] . Moreover, a study performed by Lang et al [76] , showed that IFN-γ and 397 IL-4 downregulate the SARS-CoV receptor ACE2 in VeroE6 cells, and similarly, stimulation of 398 A549 cells with IFN-α, IFN-γ, and IFN-α+IFN-γ did not identify ACE2 as an ISG [77] . 399 A feasible explanation for the decrease of ACE2 protein production upon IL-1 β treatment is 400 that IL-1β activates disintegrin and metalloproteinase domain-containing protein 17 (ADAM17) 401

[78], which mediates the shedding of ACE2 [79] . Although this effect would seem positive to 402 reduce SARS-CoV-2 infection, ACE2 is a lung-protective factor, as it converts Angiotensin (Ang) 403 II to Ang-(1-7); while Ang II promotes harmful effects in the lung, e. g. fibrosis, vasoconstriction, 404 inflammation, endothelial dysfunction, edema, and neutrophil accumulation[80], Ang-(1-7) has 405 counter-regulatory effects protective of lung injury. Moreover, Ang-(1-7) plays an essential role 406 in hemostasis, as it favors anti-thrombotic activity in platelets [81] . In any case, treatment of 407 COVID-19 patients with respiratory insufficiency and hyper inflammation with IL-1 inhibitors was 408 associated with a significant reduction of mortality [82] , indicating that at least during severe 409 COVID-19 the overall effect of IL-1β is detrimental. While the reduction of ACE2 expression in 410 AT-II cells by IL-1β may be of interest, it needs to be determined if in combination with other 411 cytokines rapidly induced during viral respiratory infection [83] , this effect would remain. 412

Further, glucocorticoids and NSAIDS have been linked to ACE2 upregulation previously [16] . In 413 contrast, we did not observe any significant impact of ibuprofen, cortisol, dexamethasone and 414 prednisone on ACE2 protein expression. These results are concordant with a recent report 415

showing that suppression of cyclooxygenase (COX)-2 by two commonly used NSAIDs, ibuprofen 416 and meloxicam, had no effect on ACE2 expression, viral entry, or viral replication in a mouse 417 model of SARS-CoV-2 infection [84] . Moreover, dexamethasone incompletely reduced viral 418 entry. This observation partially agrees with a study using lung cells previously treated with 419 dexamethasone, which showed significant suppression of SARS-CoV-2 viral growth [25] . 420

We additionally show the interest of the HLT model to test local inflammation and evaluate 421 potential anti-inflammatory drugs. The culture of diverse cell subsets localized in the lung parenchyma, without further cell separation, allows the detection of inflammatory responses 423 generated by different resident subpopulations, which is a significant advantage over 424 monoculture. Several resident-myeloid subsets, together with newly recruited ones, may 425 contribute to the rapid cytokine storm detected in . Thus, the 426 identification of antiviral drugs that can also limit the extent of these initial pro-inflammatory 427 events may offer added value to the overall therapeutic effect of a given drug. In this sense, we 428 observed that camostat significantly reduced the expression of proinflammatory molecules IL-6 429 and CXCL10 in several myeloid CD11b + subsets. Concordantly, in a previous study using primary 430 cultures of human tracheal epithelial cells infected with H1N1 virus, camostat also reduced the 431 concentrations of the cytokines IL-6 and TNF in cell supernatants [88] , suggesting a potent anti-432 inflammatory potential. In contrast, ivermectin did not affect the expression of cytokines in our 433 model. However, ivermectin was previously shown to have protective anti-inflammatory effects 434 in mice, reducing the production of TNF, IL-1 and IL-6 in vivo and in vitro [89] . Of note, in our 435 system we optimized the detection of changes for the intracellular expression of IL-6 and CXCL10 436 by local myeloid cells, and thus, how these intracellular changes reflect total production in 437 supernatant needs further evaluation. 438

Finally, it is also important to note the potential limitations of the model. First, we did not 439 maintain the cells in an air-liquid interface, which may alter cell function. Other limitations 440 include the limited availability of human lung samples, inter-patient variation (age, smoking, 441 etc.), the effects on lung biology of the medical condition instigating surgery, and the exact 442 location of the sample resection, which may affect the proportion of cell subsets such as However, this variability is what shapes the HLT into a more physiological and relevant model in 444 comparison to current methods based on immortalized cell cultures. Besides the interest of the 445 different readouts from HLT cell-based system as proposed here, our results highlight drugs with 446 antiviral activity together with immunomodulatory properties, which could increase the benefit 447 of a given treatment during COVID-19 disease progression. For instance, camostat, 448 cepharanthine and ergoloid were three of the most potent drugs inhibiting SARS-CoV-2 entry, 449 and remarkably, also exerted a significant anti-inflammatory effect on myeloid cells. Clinical 450 trials with camostat, ergoloid and cepharanthine, ideally administrated during early infection, 451

should shed light on their use as both antivirals and anti-inflammatory compounds.

VeroE6, isolated from kidney epithelial cells of an African green monkey, were grown in 455 DMEM medium supplemented with 10% fetal bovine serum (FBS; Gibco) 100 U/ml penicillin, 456 and 100 µg/ml streptomycin (Capricorn Scientific) (D10) and maintained at 37°C in a 5% CO 2 457 incubator. 458

The spike of the SARS-CoV-2 virus (D614G variant) was generated (GeneArt Gene Synthesis, 459

ThermoFisher Scientific) from the codon-optimized sequence obtained by Ou et al. respectively. For TMPRSS2 detection, after ACE2 staining with the appropriate secondary 499 antibody, cells were washed twice with PBS 1% NMS (normal mouse serum) and then stained 500 with a secondary goat anti-rabbit IgG (AF488, Thermofisher) for 30 min at 4ºC. For SPC detection, 501 after surface staining with a primary rabbit anti-SPC antibody (Biorbyt) and instead of ACE2 502 staining, cells were stained with a secondary donkey anti-rabbit IgG (PE, Biolegend) for 30 min 503 at 4 ºC. After fixation with PBS 2% PFA, cells were acquired in an LSR Fortessa (BD Biosciences), 504 and data were analyzed using the FlowJo v10.6.1 software (TreeStar). 505

Cytospin preparations were obtained from freshly isolated human lung cells at an 507 approximate density of 150,000 cells/slide, and air-dried during 15 min. Cells were stained with 508 alkaline phosphatase, as an enzyme marking epithelial type II cells, following manufacturer's 509 instructions (Alkaline phosphatase Kit, Sigma). The intensity of pink stain reflects the amount of 510 alkaline phosphatase in positive cells. 511

Human lungs were maintained in 10% formalin for 24 hours and then embedded in paraffin. 513

Paraffin-embedded lungs were cut into 4 µm sections. After removing the paraffin, endogenous 514 peroxidases were inactivated in an aqueous solution containing 3% H 2 O 2 and 10% methanol and 515 antigen retrieval was performed heating the samples in citrate buffer (10mM citric acid, pH 6.0).

The sections were then blocked in bovine serum albumin (5%), incubated with anti-ACE2 517 antibody (R&D Systems cat. nº AF933, dilution 1:100) and with biotinylated secondary antibody 518 against goat IgGs (Vector Laboratories cat. nº BA-9500, dilution 1:250). Proteins were visualized 519 using the ABC Peroxidase Standard Staining Kit (ThermoFisher) followed by 3,3′-520 Diaminobenzidine (DAB) Enhanced Liquid Substrate System (Sigma Aldrich). Counterstaining 521 was done with hematoxylin. 522

The complete list of compounds tested in this study, including information about its clinical 524 use, product reference and vendors is shown in Table S1 . Duplicates of five-fold serial dilutions 525

of 39 antiviral compounds were tested in both VeroE6 cell line and in human lung tissue (HLT) 526 cells using at least 2 different donors. For VeroE6, five-fold serial dilutions of the compounds, 527 ranging from 100µM to 0.25nM, were prepared in D10 in a 96-well flat-bottom plates. VeroE6 528 cells were added at a density of 30.000 cells/well and incubated with the drug for at least 1 h 529 before infection. Subsequently, cells were infected with 1,500 TCID 50 of VSV*ΔG(Luc)-S virus. In 530 parallel, drug cytotoxicity was monitored by luminescence. To evaluate the antiviral activity of 531 drugs in HLT cells, five-fold serial dilutions of the compounds, ranging from 100µM to 0.8µM or 532 6.4nM, were prepared in R10 in a 96-well conic-bottom plates. HLT cells were added at a density 533 of 300,000 cells/well and incubated with the compound for at least 1h before infection. Then, 534 MOI 0.1 of VSV*ΔG(Luc)-S virus were added to wells, and plates were spinoculated at 1,200g 535 and 37ºC for 2h. After infection, fresh medium was added to the wells and cell suspensions were 536 transferred into a 96-well flat-bottom plate. Cells were then cultured overnight at 37°C in a 5% 537 CO 2 incubator. Each plate contained the following controls: no cells (background control), cells 538 treated with medium (mock infection) and cells infected but untreated (infection control). After 539 20h, cells were incubated with Britelite plus reagent (Britelite plus kit; PerkinElmer) and then 540 transferred to an opaque black plate. Luminescence was immediately recorded by a 541 luminescence plate reader (LUMIstar Omega). To evaluate cytotoxicity, we used the CellTiter-542

Glo® Luminescent kit (Promega), following the manufacturer's instructions. Data was 543 normalized to the mock-infected control, after which EC 50 and CC 50 values were calculated using 544

Graph-Pad Prism 7. 545

These experiments were performed in a BSL3 facility (Viral Vector Production Unit, 547

Universitat Autònoma de Barcelona, UAB). The SARS-CoV-2 virus was isolated from a nasopharyngeal swab from an infected patient hospitalized at the Vall d'Hebron Hospital. 549

VeroE6 cells were cultured on a cell culture flask (25 cm 2 ) at 1.5 × 10 6 cells overnight prior to 550 inoculation with 1 mL of medium from a Deltaswab VICUM® tub containing the swab. Cells were 551 cultured for 1h at 37°C and 5% CO 2 . Afterwards, DMEM containing 2% FCS were added to the 552 cells and incubated for 48h. Cells were assessed daily for cytopathic effect and the supernatant 553 was recollected and subjected to viral titration in VeroE6 by plaque assay. 554

For antiviral drug validation, HLT samples were incubated with different drugs at 20µM for 555 at least 1h before infection. Tested drugs were camostat, cepharanthine, ergoloid, 556 hydroxychloroquine, ivermectin and ciclesonide. Then, cells were infected with a MOI 0.5 of the 557 SARS-CoV-2 viral isolate, and the plate was incubated for 2h at 37ºC and 5% CO2. 

VeroE6 and lung cells were incubated with five-fold serial dilutions of selected anti-575 inflammatory compounds (ranging from 100µM to 0.8µM) for 20h. Tested drugs included 576 cortisol, ibuprofen, prednisone and dexamethasone. Lung cells were also incubated with the 577 following cytokines: GM-CSF (100 ng/ml, Immunotools), IL-1β (10 ng/ml, Immunotools), IL-10 578 (100 ng/ml, Immunotools), IFN-β (100 U/ml, Immunotools), or IFN-α2 (100 U/ml, Sigma Aldrich). 579

For determination of ACE2 expression, the following surface staining antibodies were used: 580 primary goat anti-ACE2 (R&D Systems), anti-CD45 (AF700, BioLegend), anti-EpCAM (APC, BioLegend), and anti-HLA-DR (BV421, BioLegend). For ACE2 detection, cells were then stained 582 with secondary donkey anti-goat IgG (PE, R&D Systems) for 30 min at 4 ºC. A Fluorescent Minus 583

One control (FMO) without primary anti-ACE2 antibody was used as a control. Cell viability was 584 determined using an AQUA viability dye for flow cytometry (LIVE/DEAD fixable AQUA, 585 Invitrogen). After fixation with PBS 2% PFA, cells were acquired in an LSR Fortessa (BD 586 Biosciences) and analyzed using the FlowJo v10.6.1 software (TreeStar). BioLegend), and anti-CXCL10 (PE, BioLegend). Cell viability was determined using an AQUA 600 viability dye for flow cytometry (LIVE/DEAD fixable AQUA, Invitrogen). After fixation with PBS 601 2% PFA, cells were acquired in an LSR Fortessa (BD Biosciences), and data were analyzed using 602 the FlowJo v10.6.1 software (TreeStar). 603

Statistical analyses were performed with Prism software, version 6.0 (GraphPad). A P value 605 <0.05 was considered significant. 606 

EC 50 (µM) Camostat no effect 3.30 Valaciclovir no effect >100 Phenformin no effect 38.16 Eriodictyol no effect 90 Quercetin >100 no effect 

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl 626

Remdesivir for the Treatment of Covid-19 -Final Report

Therapeutically administered ribonucleoside 630 analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, 633 a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2

Dexamethasone in Hospitalized Patients with Covid-19

In Vitro and Animal Models for SARS-CoV-2 research

Exogenous ACE2 expression allows refractory cell lines to support 640 severe acute respiratory syndrome coronavirus replication

Heterogeneous expression of the SARS-Coronavirus-2 receptor ACE2 in 643 the human respiratory tract. EBioMedicine

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in 645 the Respiratory Tract

Host Cell Proteases Drive Early or Late SARS-CoV-2 Penetration. bioRxiv

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is 649 Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in 651

Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic 654 rats

Does Ibuprofen Worsen COVID-19? Drug Saf

COVID-19 and Avoiding Ibuprofen

Glucocorticoids improve severe or critical COVID-19 by activating ACE2 659 and reducing IL-6 levels

Single-cell longitudinal analysis of SARS-CoV-2 infection in human 661 airway epithelium identifies target cells, alterations in gene expression, and cell state 662 changes

A human-airway-on-a-chip for the rapid identification of candidate antiviral 664 therapeutics and prophylactics

Imbalanced Host Response to SARS-CoV-2 Drives Development 666 of COVID-19

An organoid-derived bronchioalveolar model for SARS-CoV-2 668 infection of human alveolar type II-like cells

Human organoids: model systems for human biology 670 and medicine

Upregulation of IL-17A/F from human lung tissue explants with cigarette 672 smoke exposure: implications for COPD

Oxidative modification of albumin in the parenchymal lung tissue of 674 current smokers with chronic obstructive pulmonary disease

Defining the inflammatory signature of human lung explant tissue 677 in the presence and absence of glucocorticoid

In vitro infection of human lung tissue with SARS-CoV-2: 679 Heterogeneity in host defense and therapeutic response. bioRxiv

Fraction of MHCII and EpCAM expression characterizes distal lung 682 epithelial cells for alveolar type 2 cell isolation

Epithelial MHC Class II Expression and Its Role in Antigen Presentation 684 in the Gastrointestinal and Respiratory Tracts

Flow-cytometric method for simultaneous analysis of mouse lung 686 epithelial, endothelial, and hematopoietic lineage cells

Human Lung Mononuclear Phagocytes in Health and Disease. Front 689 Immunol

Immortalisation of primary human alveolar epithelial lung cells using 691 a non-viral vector to study respiratory bioreactivity in vitro

Surfactant Protein-C in the 694 Maintenance of Lung Integrity and Function

When Is an Alveolar Type 2 Cell an Alveolar Type 2 Cell? A 696 Conundrum for Lung Stem Cell Biology and Regenerative Medicine

Single cell RNA sequencing of 13 human tissues identify cell types and 699 receptors of human coronaviruses

CD147-spike protein is a novel route for SARS-CoV-2 infection to host 702 cells

The scRNA-seq Expression Profiling of the Receptor ACE2 and the Cellular 704

Protease TMPRSS2 Reveals Human Organs Susceptible to SARS-CoV-2 Infection

SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in 707 bronchial transient secretory cells

AXL is a candidate receptor for SARS-CoV-2 that promotes infection of 709 pulmonary and bronchial epithelial cells

Generation of SARS-CoV-2 Spike Pseudotyped Virus for Viral 711 Entry and Neutralization Assays: A 1-Week Protocol. Front Cardiovasc Med

Vesicular stomatitis virus pseudotyped with severe acute respiratory 714 syndrome coronavirus spike protein

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS 716 coronavirus-induced lung injury

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its 718 immune cross-reactivity with SARS-CoV

Docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 721 Interface

Methods in plant biochemistry: assays for bioactivity

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of 725 Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome 726 Coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine use against SARS-CoV-2 infection in non-728 human primates

Virtual Screening of Potential Inhibitors for SARS-CoV-2 Main 730 Protease. 2020, Preprints.org

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-732 related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients 735 hospitalized with Covid-19-a double-blind randomized controlled trial

Inhaled biguanides and mTOR inhibition for influenza and coronavirus 738 (Review)

The pharmacological and biological roles of eriodictyol

Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator 742 TMPRSS2 with camostat and nafamostat

A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by 744 enhancing expression of ACE2

Immunology of COVID-19: Current State of the Science

A narrative review of the potential pharmacological influence and safety 748 of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a 749 dichotomy of expectation and reality

Peripheral and lung resident memory T cell responses against 752 SARS-CoV-2

Tissue distribution of ACE2 protein, the functional receptor for SARS 754 coronavirus. A first step in understanding SARS pathogenesis

Cell entry mechanisms of SARS-CoV-2

Expression of SARS-CoV-2 entry factors in lung epithelial stem cells 759 and its potential implications for COVID-19

Laboratory biosafety measures involving SARS-CoV-2 and the 761 classification as a Risk Group 3 biological agent

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike 763 Glycoprotein

SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, 765 rapid adaptation and cytopathology

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-767 Approved Drugs

Cepharanthine: a review of the antiviral 769 potential of a Japanese-approved alopecia drug in COVID-19

Chloroquine does not inhibit infection of human lung cells with 772 SARS-CoV-2

Randomized double-blinded placebo-controlled trial of 774 hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-775

A Randomized Trial of Hydroxychloroquine as Postexposure 777 Prophylaxis for Covid-19

Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A 779 Randomized-Controlled Trial

Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated 781 by TMPRSS2

SARS-CoV-2 infection of primary human lung epithelium for COVID-19 783 modeling and drug discovery

Hydroxychloroquine in COVID-19: Potential Mechanism of Action 785 Against SARS-CoV-2

Ivermectin and COVID-19: A report in Antiviral Research, widespread 787 interest, an FDA warning, two letters to the editor and the authors' responses

The effect of early treatment with ivermectin on viral load, symptoms 790 and humoral response in patients with non-severe COVID-19: A pilot, double-blind, 791 placebo-controlled, randomized clinical trial. EClinicalMedicine

Interferons and viruses induce a novel truncated ACE2 isoform and 793 not the full-length SARS-CoV-2 receptor

Tissue-specific and interferon-inducible expression of nonfunctional 795 ACE2 through endogenous retroelement co-option

Antiviral Activity of Type I, II, and III Interferons Counterbalances 798 ACE2 Inducibility and Restricts SARS-CoV-2. mBio

Interferon-gamma and interleukin-4 800 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells

Extreme heterogeneity of influenza virus 803 infection in single cells

Interleukin-1 stimulates ADAM17 through a mechanism 805 independent of its cytoplasmic domain or phosphorylation at threonine 735

TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis 808 by TMPRSS2 augments entry driven by the severe acute respiratory syndrome 809 coronavirus spike protein

The four horsemen of a viral Apocalypse: The pathogenesis of SARS-811

CoV-2 infection (COVID-19). EBioMedicine

The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas 813 receptor axis: a potential target for treating thrombotic diseases

Interleukin-1 and interleukin-6 inhibition compared with standard 816 management in patients with COVID-19 and hyperinflammation: a cohort study

Single-cell landscape of bronchoalveolar immune cells in patients with 819 COVID-19

Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and 821

Antibody Response to SARS-CoV-2 Infection

Frontline Science: COVID-19 infection induces readily detectable 824 morphologic and inflammation-related phenotypic changes in peripheral blood 825 monocytes

Cellular events of acute, resolving or progressive COVID-19 in 827 SARS-CoV-2 infected non-human primates